This book provides current information on the development of molecular imaging probes for cancer research, and should be useful to a broad audience interested in molecular imaging and cancer research. It is expected that the readers will include undergraduate, graduate, and medical students, residents, physicians, and scientists with backgrounds from various physical, chemical, biological, and medical specialty areas. This book consists of 34 chapters that are organized into five sections. The chapters were contributed by over 80 authors worldwide, who are among the world's prominent scientists in their fields.
Section I talks about the fundamentals of molecular imaging and consists of four chapters. Chapter 1 assumes that cancer is a genetic disease and discusses how cancer is different from other diseases, its causes and prevalence, current approaches on diagnosis and treatment, and future directions. Chapter 2 describes the basics of molecular imaging instrumentation. These imaging technologies exploit energy emissions that span nearly the entire range of the electromagnetic spectrum. Chapter 3 explains the basic principles, techniques and software tools involved in the process of molecular imaging data analysis and quantification. Chapter 4 defines the characteristics of a clinically translatable molecular imaging probe to be of high contrast, of high target affinity and specificity, sensitive enough to detect small number of targets, metabolically stable, with little to no pharmacological effect, and ease of production.
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Section II focuses on radionuclide labeled molecular imaging probes and consists of nine chapters. Chapter 5 describes the production of positron emitting radionuclides and how different positron emission tomography (PET) isotopes are incorporated into biologically active molecules. Chapter 6 introduces the coordination chemistry of two most commonly used single-photon emission tomography (SPECT) isotopes, 99m Tc and 111 In. The design of bifunctional chelators for these two radiometals and subsequent bioconjugation are elaborated. Chapter 7 reviews how tumor metabolism, including glucose metabolism, amino acid transport and protein synthesis, choline metabolism, and fatty acid synthesis and acetate metabolism, can be imaged for tumor detection, staging, and monitoring of therapy response. Chapter 8 looks into tumor proliferation process and argues that both indirect and direct imaging of DNA synthesis may be able to reflect the proliferative status of a tumor. The ultimate goals of tumor proliferation imaging are to improve the diagnosis, grading and staging of cancer as well as to predict the treatment response in individual patients after the initiation of antitumor therapy. Chapter 9 reports use of various imaging techniques to visualize the changes of caspase activity, phosphatidylserine externalization, and mitochondrial membrane potential indicative of apoptosis induced by cancer therapy. Chapter 10 recognizes the importance of tumor hypoxia as a key factor responsible for tumor resistance to chemotherapy and radiotherapy and reviews the status quo of tumor hypoxia imaging, pointing out the known variables and problems with our current ability to measure tumor hypoxia. Chapter 11 gives insights into multidrug resistance (MDR) and how nuclear medicine imaging can be applied to image the drug efflux pumps related to adenosine triphosphate binding cassette (ABC) transporters, Pglycoprotein (PgP) and multidrug resistance protein (MRP). Chapter 12 agrees that tumor angiogenesis plays a vital role in tumor growth and metastatic spread and highlights the recent advances of PET and SPECT imaging of several tumor vasculature markers, namely, integrins, vascular endothelial growth factor (VEGF) and its receptors (VEGFRs), prostate-specific membrane antigen (PSMA), and matrix metalloproteinases (MMPs). Chapter 13 overviews currently validated PET and SPECT reporter gene and reporter probe systems and their applications in gene therapy, regulation of endogenous genes, cell therapy and organ transplantation and cancer monitoring.
Section III covers non-radionuclide molecular imaging probes in cancer research and consists of 14 chapters: Chapters 14-19 focus on the recent progresses in optical imaging probe development with emphasis on unique chemistry designs and their imaging applications. Chapter 14 introduces the chemistry of fluorescent probes. Chapter 15 exemplifies the use of near-infrared fluorescent dye conjugates to image receptors, enzymes, proteases, and transporters aberrantly expressed in Chapter 25 illustrates the use of targeted microbubble contrast agents to image tumor angiogenesis, microvascular perfusion and blood volume. Chapter 26 demonstrates the potential of high intensity focused ultrasound (HIFU) for accurately ablating tissue deeper down in the body and for improving the local delivery of a variety of anti-cancer agents. Chapter 27 reviews the basic principles of X-ray physics, production and detection, and imaging via radiography and tomography and the characterization of both existing contrast agents and emerging polymer and nanoparticle materials.
Section IV covers the topics of multimodality imaging and consists of three chapters. Chapter 28 introduces several important multimodality instrumentations that integrate the strengths of two or more modalities to eliminate one or more weaknesses of an individual modality, thus offer the prospect of improved diagnostics, therapeutic monitoring, and preclinical research using imaging approaches. Chapter 29 emphasizes the importance of multifunctional probes for multimodality imaging of cancer and proposes theragnostic agents that allow simultaneous imaging and therapy for future individualized treatment of cancer patients. Chapter 30 analyzes the pros and cons of direct and indirect cell labeling in the evaluation of tumor establishment, growth, progression, metastasis and response to therapy.
Section V covers the applications of cancer molecular imaging probes and consists of four chapters. Chapter 31 reviews the state of the art of anatomical, functional and molecular imaging cancer progression, metastasis and recurrence at the earliest stage. Chapter 32 introduces the theragnostic strategy that combines a diagnostic test with a therapeutic entity in order to identify patients who will likely benefit from a specific therapeutic intervention, fail to respond or eventually manifest side effects to a given drug. Chapter 33 describes the use of molecular imaging as a tool for cancer drug development. Non-invasive molecular imaging helps decision-making, provides valuable biological markers or surrogate end points of drug efficacy, and produces substantiating evidence for a claim during the registration of a new drug. Chapter 34 walks through the procedures of clinical translation of both radiopharmaceuticals and non-radioactive molecular imaging probes and provides perspectives on future need of new mechanism-based imaging agents.
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Introduction
Cellular organization in every multi-cellular organism is structured with the necessary complexity that the organism is expected to face in its lifetime. The genome of every cell in a multi-cellular organism must carry the complete information needed for it to maintain the integrity of the cell, the integrity of the organism, and the integrity of the stored information in the genome. Hence, the maintenance of cellular integrity is more complex than was once assumed. When there is a break in this integrated circuit by one or more means, it can lead to the development of complex changes in the cells that may not be reversible, which in turn can affect the whole organism. Earth currently supports an estimated 10 million species, each with its own distinct species-specific genome.
1 Each species' genome is intended to reproduce its own progeny with unique genetic makeup and functional organization. This complex phenomenon was achieved through a strict maintenance of genomic integrity. Changes or insults to this complex, highly maintained genomic integrity can lead to significant effects that are not reversible.
Cancer is one of several devastating diseases that have evolved through the mechanism of altering the complex genomic integrity of cells. Cancer is a disease of the genome at cellular level. This understanding of cancer has been confirmed by much relatively new evidence, and today most significant work on cancer is focused on: (1) elucidating the mechanism of the development cancer cells from normal cells, (2) finding ways to prevent cancer development, and 3) developing drugs to treat cancer in progress (i.e., various means of specifically targeting and killing cancer cells). There is little focus or proposed work on finding possible mechanisms by which a cancer cell or a particular type of cancer tissue can be reverted back into normal cell or tissue. For the most part, researchers are not hopeful that, once mutated, cancer cells can be realistically transformed back in to normal cells, given the difficulty in understanding the complex process of cancer development.
Until the end of the 18th century cancer was assumed to be associated with the entry of foreign particles into the body that grew into tumor over time. 2 Later, in the early 19th century, scientists came to understand that cancer cells grew out of normal body cells. As recently as the mid-1970s, the main cause for cancer development was linked mostly with the viruses that infect human cells and develop tumors by activating cellular oncogenes (Figs. 1a and b) .
3-9 Although this is a mechanism involved in the development of some types of cancers (e.g., Hepatitis B virus, which leads to liver cirrhosis and eventually to hepatocellular carcinoma; Papilloma virus, which can cause cervical cancer in women), it is by no means the exclusive mechanism involved in development of all forms of cancer (Figs. 1c and d) . We now know that cancer can result from common
